Cytokinetics Presents Positive Aficamten Data for Obstructive HCM at European Heart Failure Congress

Cytokinetics Incorporated (NASDAQ:CYTK) is one of the most active stocks to buy according to analysts. Earlier in May, Cytokinetics announced the presentation of additional data regarding aficamten at the European Society of Cardiology Heart Failure 2025 Congress. The new findings stem from two analyses of SEQUOIA-HCM, the pivotal Phase 3 clinical trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy/HCM. Additionally, results from a real-world analysis concerning non-obstructive HCM were also presented.

The efficacy data of aficamten in obstructive HCM patients with mild symptoms from SEQUOIA-HCM were simultaneously published in The European Heart Journal. The Vice President and Head of Clinical Research at Cytokinetics, Stephen Heitner, M.D., stated that these analyses from SEQUOIA-HCM show that aficamten’s effects on exercise capacity, symptoms, hemodynamics, and cardiac biomarkers are consistent across patients with obstructive HCM, regardless of their baseline symptom severity or geographic region.

Aficamten is an investigational selective and small-molecule cardiac myosin inhibitor designed to reduce myocardial hypercontractility in HCM by preventing myosin from entering a force-producing state. It has received Breakthrough Therapy Designation from the US FDA for symptomatic HCM and from China’s NMPA for symptomatic obstructive HCM.

The drug is currently under regulatory review in the US, with a Prescription Drug User Fee Act/PDUFA target action date of December 26 this year. It is also under review by the European Medicines Agency/EMA and the Center for Drug Evaluation/CDE of China’s National Medical Products Administration/NMPA with Priority Review.

Cytokinetics Incorporated (NASDAQ:CYTK) is a late-stage biopharmaceutical company that discovers, develops, and commercializes muscle activators and inhibitors as potential treatments for debilitating diseases in the US.

While we acknowledge the potential of CYTK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.